These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17335704)

  • 21. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
    Guo N; Marra F; Fitzgerald JM; Elwood RK; Marra CA
    Eur Respir J; 2010 Jul; 36(1):206-8. PubMed ID: 20595167
    [No Abstract]   [Full Text] [Related]  

  • 22. Recurrent acute pancreatitis after isoniazid.
    Chow KM; Szeto CC; Leung CB; Li PK
    Neth J Med; 2004 May; 62(5):172-4. PubMed ID: 15366703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteoarticular tuberculosis: current diagnosis and treatment.
    Sequeira W; Co H; Block JA
    Am J Ther; 2000 Nov; 7(6):393-8. PubMed ID: 11304648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isoniazid-induced recurrent pancreatitis.
    Mattioni S; Zamy M; Mechai F; Raynaud JJ; Chabrol A; Aflalo V; Biour M; Bouchaud O
    JOP; 2012 May; 13(3):314-6. PubMed ID: 22572141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute pancreatitis induced by isoniazid.
    Izzedine H; Launay-Vacher V; Storme T; Deray G
    Am J Gastroenterol; 2001 Nov; 96(11):3208-9. PubMed ID: 11721781
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute pancreatitis induced by isoniazid in the treatment of tuberculosis.
    Stephenson I; Wiselka MJ; Qualie MJ
    Am J Gastroenterol; 2001 Jul; 96(7):2271-2. PubMed ID: 11467674
    [No Abstract]   [Full Text] [Related]  

  • 27. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
    Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
    Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multifocal osteoarticular tuberculosis.
    Shah BA; Splain S
    Orthopedics; 2005 Mar; 28(3):329-32. PubMed ID: 15790095
    [No Abstract]   [Full Text] [Related]  

  • 30. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
    Colebunders R; Florence E
    Lancet; 1998 Jun; 351(9118):1813. PubMed ID: 9635977
    [No Abstract]   [Full Text] [Related]  

  • 32. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Short-term treatment of tuberculosis with and without pyrazinamide in the second phase (TA-80)].
    Farga V; Valenzuela P; Yañez A; Valenzuela MT; Scheel G; Mendoza F; Torres E; Icekson I; Grinspun M; Fernández M
    Rev Med Chil; 1983 Jul; 111(7):750-4. PubMed ID: 6680460
    [No Abstract]   [Full Text] [Related]  

  • 34. Tuberculous sacro-ileitis: two cases and radiological findings.
    Sirmatel O; Yazgan P; Gursoy B; Sirmatel F; Zeyrek FY; Ozturk A
    Infez Med; 2007 Jun; 15(2):119-23. PubMed ID: 17599000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cutaneous reaction after pyrazinamide initiation].
    Mulliez P; Mbassi Fouda FL; Roy Saint-Georges F
    Med Mal Infect; 2011 Sep; 41(9):499-500. PubMed ID: 21458177
    [No Abstract]   [Full Text] [Related]  

  • 36. Tuberculosis control programme guidelines--treatment regimens.
    Durrheim DN; Belt EL
    S Afr Med J; 1996 Oct; 86(10):1293-4. PubMed ID: 8955740
    [No Abstract]   [Full Text] [Related]  

  • 37. [Addisonian crises induced by rifampicin].
    Campos-Varela I; Perich-Jackson D; Ferrer-Sancho J
    Arch Bronconeumol; 2006 Jul; 42(7):376. PubMed ID: 16945269
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Acute pancreatitis induced by isoniazid, a casual association].
    Mendoza JL; Larrubia JR; Lana R; Espinós D; Díaz-Rubio M
    An Med Interna; 1998 Nov; 15(11):588-90. PubMed ID: 9882856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of isoniazid-induced liver injury diagnosed by use of the DLST, and successful reintroduction of isoniazid for pleural tuberculosis.
    Ikegame S; Wakamatsu K; Fujita M; Nakanishi Y; Kajiki A
    J Infect Chemother; 2011 Aug; 17(4):530-3. PubMed ID: 21188445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.